Aimmune Expects ‘Robust’ Demand For Peanut Allergy Treatment Palforzia, Though Slow Launch
The COVID-19 Pandemic Is Expected To Affect The Launch
Aimmune CEO Jayson Dallas talked to Scrip about the company's field team, allergists' and payers' responses to the first food-derived medicine, and why Viaskin Peanut patch is not a competitive threat.
You may also be interested in...
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.
Coronavirus Update: Drug Launches Could Be Hit, New Twist In CureVac Controversy, Moderna Doses First Patient
As western Europe and the US roll out the next wave of lockdown measures to limit the spread of COVID-19, biopharma is continuing efforts to accelerate therapies and vaccines, including Moderna starting Phase I trials.
Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.